10 unknown, 6 completed, 4 not yet recruiting, 3 recruiting. 11 Phase 2, 5 Not applicable, 4 Phase 3, 1 Phase 1.
Follow Capecitabine: new trials by email Literature Review of Capecitabine trials Research Report on Capecitabine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab - Local Advanced Rectal Cancer, PD-1 Inhibitor | Phase 3 | Not yet recruiting | Guangdong Provincial People's Hospital | 148 | 2027-01-01 | 2026-07-07 |
| Total Neoadjuvant Therapy With Additional Consolidation Chemotherapy Followed by Local Excision Versus Total Neoadjuvant Therapy Followed by Local Excision at Stage I Rectal Cancer TNT with additional consolidation chemotherapy followed by local excision, TNT followed by local excision - Organ Preservation, Rectal Cancer Stage I | Not applicable | Not yet recruiting | Seoul National University Hospital | 292 | 2026-06-01 | 2026-05-04 |
| Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome True electroacupuncture + True self-administered acupressure, Doctor-prescribed treatment, Sham electroacupuncture + Sham self-administered acupressure - Capecitabine, Hand-foot Syndrome | Not applicable | Recruiting | Affiliated Hospital of Qinghai University | 220 | 2024-10-08 | 2024-12-12 |
| First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study mCapOX plus Cetuximab, mFOLFOX6 plus Cetuximab - Colorectal Cancer (CRC), Capecitabine | Phase 3 | Not yet recruiting | Meng Qiu | 452 | 2024-09-26 | 2024-09-27 |
| NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab - Nanoliposomal Irinotecan, Cadonilimab | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 30 | 2024-04-17 | 2024-12-24 |
| Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC concurrent radiotherapy with envafolimab and capecitabine - Pancreatic Cancer, Radiotherapy | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 43 | 2024-01-31 | 2024-01-19 |
| Topical Diclofenac for Hand-Foot Syndrome Prevention in Colorectal and Gastric Cancer on Capecitabine (DICLO-HFS) Colorectal Cancer, Gastric Cancer (GC) | Completed | Gazi University | 151 | 2023-07-30 | 2025-09-17 | |
| XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine - Tislelizumab, Bevacizumab | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 52 | 2023-07-07 | 2023-08-01 |
| Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer Tislelizumab - MSI-H Colorectal Cancer, Tislelizumab | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 25 | 2023-06-01 | 2023-05-09 |
| A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients fruquintinib, Irinotecan, Capecitabine - Fruquintinib, Irinotecan | Unknown | China Medical University, China | 50 | 2023-06-01 | 2023-12-13 | |
| UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases UTD1 combined with capecitabine - Metastatic HER2 Negative Breast Carcinoma, Brain Metastases | Phase 1 / Phase 2 | Recruiting | Hunan Cancer Hospital | 30 | 2023-01-01 | 2025-04-25 |
| Efficacy of Extra Virgin Olive Oil (EVOO) Supplementation on Hand-Foot Syndrome Incidence in Patients With Capecitabine Extra Virgin Olive Oil, Olive Oil, Placebo - Hand and Foot Skin Reaction, Hand and Foot Syndrome | Not applicable | Unknown | Universitas Sriwijaya | 60 | 2023-01-01 | 2024-01-03 |
| Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma SBRT radiotherapy + Conventionally fractionated radiotherapy, PD-1 inhibitor, Capecitabine - Radiotherapy, PD-1 Inhibitor | Phase 2 | Withdrawn | Fifth Affiliated Hospital, Sun Yat-Sen University | 2022-03-28 | 2026-09-23 | |
| Pharmaceutical Care for Patients Using Capecitabine Pharmaceutical Care - Cancer Colorectal, Cancer Gi | Not applicable | Completed | Faculdade de Farmácia | 176 | 2022-03-01 | 2025-07-18 |
| The Therapeutic Effect of Different Doses of Capecitabine capecitabine - Capecitabine | Not applicable | Completed | Jingjiang People's Hospital | 150 | 2022-01-01 | 2024-02-07 |
| First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes mCapOX plus cetuximab, mFOLFOX6 plus cetuximab - Colo-rectal Cancer, Capecitabine | Phase 2 | Unknown | West China Hospital | 150 | 2021-07-21 | 2024-03-07 |
| Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. Camrelizumab, apatinib, Capecitabine - Biliary Tract Cancer, Anti-PD-1 Therapy | Phase 2 | Completed | Beijing Friendship Hospital | 28 | 2021-01-01 | 2024-01-30 |
| The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer Apatinib, Capecitabine - Stomach Neoplasms, Gastrointestinal Neoplasms | Phase 3 | Unknown | Fudan University | 242 | 2019-03-22 | 2019-03-26 |
| A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases RC48-ADC, Lapatinib, Capecitabine - Breast Neoplasms, Breast Diseases | Phase 2 / Phase 3 | Unknown | RemeGen Co., Ltd. | 301 | 2018-04-24 | 2024-02-20 |
| Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients detection of genotype - Solid Tumor, Capecitabine | Unknown | Cui Yimin | 2200 | 2017-12-28 | 2019-08-28 |
Showing 20 of 24. Sign in to see all of them.
Colorectal Neoplasms (4) · Breast Neoplasms (3) · Gastrointestinal Neoplasms (3) · Hand-Foot Syndrome (3) · Biliary Tract Neoplasms (2) · Colonic Neoplasms (2) · Drug-Related Side Effects and Adverse Reactions (2) · Stomach Neoplasms (2) · Brain Neoplasms (1) · Breast Diseases (1) · Carcinoma, Neuroendocrine (1) · Cholangiocarcinoma (1) · Digestive System Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Neoplasms (1)
Neoplasms (16) · Neoplasms by Site (16) · Digestive System Diseases (12) · Digestive System Neoplasms (11) · Gastrointestinal Diseases (9) · Intestinal Diseases (7) · Intestinal Neoplasms (7) · Colonic Diseases (6) · Gastrointestinal Neoplasms (6) · Chemically-Induced Disorders (5) · Rectal Diseases (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Carcinoma (3) · Colorectal Neoplasms (3)
Capecitabine (12) · Cetuximab (2) · Oxaliplatin (2) · apatinib (2) · Cisplatin (1) · Gemcitabine (1) · Immune Checkpoint Inhibitors (1) · Irinotecan (1) · Lapatinib (1) · Olive Oil (1) · Pharmaceutical Services (1) · Temozolomide (1) · Trinitrotoluene (1) · camrelizumab (1) · envafolimab (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Asan Medical Center (2) · Affiliated Hospital of Qinghai University (1) · Beijing Friendship Hospital (1) · China Medical University, China (1) · Cui Yimin (1) · Faculdade de Farmácia (1) · Fifth Affiliated Hospital, Sun Yat-Sen University (1) · Fudan University (1) · Gazi University (1) · Guangdong Provincial People's Hospital (1) · Hunan Cancer Hospital (1) · Jingjiang People's Hospital (1) · Meng Qiu (1) · RemeGen Co., Ltd. (1)
China (16) · South Korea (3) · Brazil (1) · Indonesia (1) · Turkey (Türkiye) (1)
Baek-Yeol Ryoo, MD (2) · Meng Qiu, M.D. (1) · Nanlin Li, Doctor (1) · Nuriye Ozdemir, MD (1) · Wansheng Chen, PhD (1) · Wei Deng (1) · Yunpeng Liu, PhD (1) · Zhigang MD Liu, PhD (1)
PMID 21940785, PMID 28715540, PMID 34213641, PMID 34332992, PMID 35686441, PMID 39102756, PMID 39132982, PMID 39532185, PMID 40803577, PMID 41468321, PMID 42623594, PMID 42802176